Characterizing the global prevalence and burden of HAND and associated factors


  • Earlier antiretroviral therapy (ART) to maintain a high level CD4 cell count may reduce HIV-associated neurocognitive disorder (HAND) prevalence and severity.

Why this matters

  • HIV-associated neurocognitive disorder (HAND) is highly prevalent globally in adults, especially in sub-Saharan Africa and Latin America, and in those with a high level of nadir CD4 count.

  • Understanding the prevalence and demographic factors contributing to HAND will allow for improved detection and more efficient management of the condition.